Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Fotemustine + S44563|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Fotemustine||Chemotherapy - Alkylating 14|
|S44563||BCL-XL inhibitor 11 BCL2 inhibitor 17||S44563 binds to BCL-2 and BCL-XL and inhibits their interaction with BH3, which potentially results in increased tumor cell apoptosis and decreased tumor growth (PMID: 24454684).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||uveal melanoma||not applicable||Fotemustine + S44563||Preclinical - Pdx||Actionable||In a preclinical study, treatment with S44563 in combination with or after Fotemustine resulted in improved efficacy compared to either agent alone in patient-derived xenograft models of uveal melanoma (PMID: 24454684).||24454684|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|